Skip to content
PubMed This is a summary of 60 peer-reviewed journal articles Updated
Pediatric Endocrinology

DEND Syndrome: A Patient and Caregiver Guide

At a Glance

DEND syndrome is a rare genetic cause of neonatal diabetes, epilepsy, and developmental delay. Testing KCNJ11 or ABCC8 can identify variants that may allow a supervised transition from insulin to a sulfonylurea while neurological and developmental care continues.

DEND syndrome is an exceptionally rare genetic condition that fundamentally changes how the body manages both energy and electrical activity. It is named for its three primary features: Developmental delay, Epilepsy, and Neonatal Diabetes. At its core, DEND is caused by a specific “glitch” in the KATP channels, which act as tiny electrical gates in the pancreas and the brain. In children with DEND, these gates stay stuck in the “open” position, preventing the pancreas from releasing insulin and disrupting the normal electrical rhythms the brain needs for movement and learning [1][2]. Some children may instead have iDEND (intermediate DEND), a version of the condition where the symptoms—particularly the neurological ones—are generally less severe [3].

Because this condition is so rare, the most critical step in determining long-term treatment is obtaining a precise genetic diagnosis, usually involving the KCNJ11 or ABCC8 genes. This genetic “map” is essential because it does more than just name the condition; it can sometimes change the entire course of treatment. For many children with specific variants, identifying the exact mutation reveals that their body can be treated with an oral medication called a sulfonylurea. This medication can often “force” the stuck gates to close, allowing the child’s own pancreas to start releasing insulin and potentially stabilizing electrical activity in the brain [4][5]. Please note: Immediate diabetes and neurological management will begin right away while genetic testing is arranged. You should never stop insulin or adjust treatments based on a guide—only under the strict supervision of your medical care team.

Living with DEND means managing a complex, multi-system condition, but it also means being part of a new era of precision medicine. While the diagnosis often begins with the intense challenge of managing a newborn’s blood sugar, a successful transition to oral medication can significantly simplify daily life by replacing insulin injections with liquid or crushed tablets. Beyond the diabetes, your child’s path will involve a dedicated team of specialists—including endocrinologists, neurologists, and therapists—who work together to support every aspect of their growth and development [6][7].

While the road ahead involves many unknowns and a wide range of possible outcomes, a DEND diagnosis provides a clear explanation for your child’s unique needs and a targeted way to address them. By focusing on early intervention, precise genetic care, and partnering with your care team, you can support your child’s development. You are not alone on this journey; though the condition is rare, the medical community’s understanding of how to treat and support individuals with DEND continues to grow [4][8].

Common questions in this guide

What is DEND syndrome?
DEND syndrome is a rare genetic condition that can cause neonatal diabetes, epilepsy, and developmental delay. It results from changes that disrupt KATP channels, which help regulate insulin release in the pancreas and electrical activity in the brain.
Which genes are tested when a child may have DEND syndrome?
Genetic testing commonly examines the KCNJ11 and ABCC8 genes. Finding the exact variant can help confirm the diagnosis and show whether the child may respond to a sulfonylurea medicine.
Can a child with DEND syndrome switch from insulin to tablets?
Some children with specific genetic variants can transition from insulin to an oral sulfonylurea, which may help the pancreas release insulin and may support neurological function. The transition must be planned and monitored by the child's medical team, and insulin should never be stopped without medical direction.
How can DEND syndrome affect a child's development and movement?
Neurological effects vary widely and may include developmental delay, epilepsy, or movement concerns. Intermediate DEND, or iDEND, generally has less severe neurological symptoms, while early intervention and therapy can support the child's development.
Which specialists usually care for a child with DEND syndrome?
Care commonly involves a pediatric endocrinologist, neurologist, and medical genetics team, along with therapists who support development. These specialists coordinate diabetes management, neurological care, genetic treatment decisions, and developmental monitoring.

Get notified when new evidence is published on DEND syndrome.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.

References

References (8)
  1. 1

    Permanent Neonatal Diabetes (DEND Syndrome).

    Khan SA, Parkash A, Ibrahim M

    Journal of the College of Physicians and Surgeons--Pakistan : JCPSP 2016; (26(11)):114-115 doi:218.

    PMID: 28666500
  2. 2

    New insights into KATP channel gene mutations and neonatal diabetes mellitus.

    Pipatpolkai T, Usher S, Stansfeld PJ, Ashcroft FM

    Nature reviews. Endocrinology 2020; (16(7)):378-393 doi:10.1038/s41574-020-0351-y.

    PMID: 32376986
  3. 3

    Successful transition to sulfonylurea therapy in two Iraqi siblings with neonatal diabetes mellitus and iDEND syndrome due to ABCC8 mutation.

    Ozsu E, Giri D, Seymen Karabulut G, Senniappan S

    Journal of pediatric endocrinology & metabolism : JPEM 2016; (29(12)):1403-1406.

    PMID: 27849623
  4. 4

    The effect of early, comprehensive genomic testing on clinical care in neonatal diabetes: an international cohort study.

    De Franco E, Flanagan SE, Houghton JA, et al.

    Lancet (London, England) 2015; (386(9997)):957-63.

    PMID: 26231457
  5. 5

    Production and purification of ATP-sensitive potassium channel particles for cryo-electron microscopy.

    Driggers CM, Shyng SL

    Methods in enzymology 2021; (653()):121-150 doi:10.1016/bs.mie.2021.02.008.

    PMID: 34099169
  6. 6

    Neonatal Diabetes Mellitus.

    Beltrand J, Busiah K, Vaivre-Douret L, et al.

    Frontiers in pediatrics 2020; (8()):540718 doi:10.3389/fped.2020.540718.

    PMID: 33102403
  7. 7

    Effectiveness and safety of long-term treatment with sulfonylureas in patients with neonatal diabetes due to KCNJ11 mutations: an international cohort study.

    Bowman P, Sulen Å, Barbetti F, et al.

    The lancet. Diabetes & endocrinology 2018; (6(8)):637-646 doi:10.1016/S2213-8587(18)30106-2.

    PMID: 29880308
  8. 8

    Sulfonylurea for improving neurological features in neonatal diabetes: A systematic review and meta-analyses.

    de Gouveia Buff Passone C, Giani E, Vaivre-Douret L, et al.

    Pediatric diabetes 2022; (23(6)):675-692 doi:10.1111/pedi.13376.

    PMID: 35657808

This page explains DEND syndrome and its genetic treatment options for informational purposes only; it does not constitute medical advice. Do not change insulin, sulfonylureas, or other care without the child's treating medical team.